 |
Prospector
Profile
1001-05
|
| |
| Astralis Limited |
NAICS |
541710 |
| 75 Passaic Avenue
Fairfield, NJ 07004 |
Description |
Biotechnology |
| (973) 227-7168 |
Employees |
1 |
| http://www.astralisltd.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.9790 |
| |
Assets |
(mil) |
0.3230 |
| |
Liability |
(mil) |
0.5340 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Astralis Ltd. had a $122,164 for the second quarter ended June 30, 2007, much lower than the $403,769 net loss booked in the second quarter of 2006. For the six months ended June 30, 2007, the Company had a $263,326 net loss, lower than the $831,012 net loss incurred in the first half of 2006. As a result of its recurring losses, the Company's balance sheet showed $32,640,538 in accumulated deficit and $469,700 in stockholder's deficit. It also has strained liquidity with $57,401 in total current assets available to pay $449,473 in total current liabilities.
|
| |
|
Intellectual Property:
In January 2004, the U.S. Patent and Trademark Office issued a patent to Dr. Jose Antonio O'Daly for the "Compositions and Methods for the Treatment and Clinical Remission of Psoriasis." In March 2002, Akiva LLC, a company owned by Dr. O'Daly, also filed an application to obtain patent protection internationally for the Psoriasis Formula under the Patent Cooperation Treaty. In addition, in August 2003, Akiva LLC filed patent applications in the European Union, Australia, Brazil, Canada, Mexico and Japan. In January 2004, Dr. O'Daly filed a patent application with the U.S. PTO focusing on the mechanism of action of PsoraxineŽ, expanding the claims to include medical indications other than psoriasis, such as Atopic Dermatitis, Psoriatic Arthritis and Rheumatoid Arthritis. In January 2004, Dr. O'Daly also filed a second patent relating to a culture medium for parasitic organisms, which is part of its technology platform. Dr. O'Daly has assigned to the Company the rights in the patents and patent applications. In January 2004, the U.S. PTO granted the Company a federal trademark registration for the mark PsoraxineŽ. [SEC Filing 10-KSB 04-17-07]
|
| |
|
Description:
The Company is engaged in the research and development of treatments for immune system disorders and skin diseases, such as psoriasis, and psoriatic and rheumatoid arthritis.
|
| |
|
Officers:
Jose Antonio O'Daly, M.D., Ph.D. (Chair, Interim CEO, CFO & Chief Scientific Officer); Manuel Tarabay (Dir.)
|
| |
|
Auditor:
Malone & Bailey PC
|
| |
|
Securities:
Common Stock-Symbol ASTR.OB; OTC BB;
91,454,873 common shares outstanding as of August 17, 2007.
|
| |
| |
| |
| return to main page |
|
|
